Finance

Lists
SPTX:NASDAQ
Seaport Therapeutics Inc
$21.74
-0.87%
(-0.19) 1D
Nov 10, 1:05:32 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SPTX...
Open
$22.00
High
$22.23
Low
$21.05
Mkt. cap
1.16B
Avg. vol.
251.54K
Volume
100.50K
52-wk high
$28.38
52-wk low
$14.85
EPS
-$2.51
No. of employees
59
Open
$22.00
High
$22.23
Low
$21.05
Mkt. cap
1.16B
Avg. vol.
251.54K
Volume
100.50K
52-wk high
$28.38
52-wk low
$14.85
EPS
-$2.51
No. of employees
59
News stories
From web sources and news partners
About Seaport Therapeutics Inc
CEODaphne Zohar
Employees59
Founded2024
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 7 analysts giving stock ratings to SPTX in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for SPTX in the last 3 months.
Highest
Current $21.74
$50.00 (+130.04%)
Average
$37.43 (+72.21%)
Lowest
$28.00 (+28.82%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tessa Romero
J.P. Morgan
Buy
Maintained
$41.00
+88.6%
11/05/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$50.00
+130%
11/04/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$30.00
+38%
11/03/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
$28.00
+28.8%
11/03/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$35.00
+61%
11/02/2026
Justin Walsh
JonesTrading
Buy
Reiterated
$32.00
+47.2%
11/02/2026
Tiago Fauth
Raymond James
Buy
Initiated
$46.00
+111.6%
09/25/2026
Rudy Li
Wolfe Research
Hold
Initiated
-
-
07/07/2026
Marc Goodman
Leerink Partners
Buy
Initiated
$35.00
+61%
05/27/2026
Last report
Nov 2, 2026
Fiscal period
Q3 2026
-$0.49 / -$0.56
+11.97%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
20.31M
20.86M
24.38M
23.73M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.99M
6.11M
41.19M
6.45M
Operating expense
25.30M
26.98M
65.57M
30.18M
Total operating expenses
25.30M
26.98M
65.57M
30.18M
Operating income
-25.30M
-26.98M
-65.57M
-30.18M
Other non operating income
39.00K
-46.00K
-34.00K
13.00K
EBT including unusual items
-22.45M
-24.89M
-62.35M
-26.27M
EBT excluding unusual items
-22.45M
-24.89M
-62.35M
-26.27M
Income tax expense
95.00K
519.00K
251.00K
127.00K
Effective tax rate
-0.42%
-2.09%
-0.40%
-0.48%
Other operating expenses
-
-
-
-
Net income
-22.54M
-25.41M
-62.60M
-26.39M
Net profit margin
-
-
-
-
Earnings per share
-
-10.34
-1.78
-0.49
Interest and investment income
2.81M
2.13M
3.26M
3.90M
Interest expense
-
-
-
-
Net interest expenses
2.81M
2.13M
3.26M
3.90M
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.24M
-26.95M
-65.55M
-30.15M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps